Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals has reported encouraging results from a Phase 2 clinical trial of eRapa™ in treating Familial Adenomatous Polyposis (FAP), showing a 75% non-progression rate and a significant reduction in polyp burden after 12 months. The trial’s success paves the way for a Phase 3 study, supported by a $17 million grant, which could potentially eliminate the need for surgical intervention in FAP patients. eRapa™, a proprietary oral tablet formulation of rapamycin, has been developed to improve bioavailability and reduce toxicity, with patent protection extending through 2035.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
